10月27日，康希诺生物盘中下跌5.1%，报27.52港元，成交额3876.27万港元。
消息面上，市场此前对海外mRNA肿瘤疫苗临床数据抱有较高预期，但莫得纳与默克联合研发的个性化黑色素瘤疫苗三期试验数据提前泄露且未达高预期，压制了相关概念股情绪。
公司已搭建mRNA开发和制备平台，并曾与德普世生物签署合作框架协议，共同开发mRNA个性化肿瘤疫苗；此前公司亦提示，海外mRNA肿瘤疫苗阶段性数据发布可能影响市场波动。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.